Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

4D Molecular Therapeutics, Inc. FDMT

Healthcare  —  Biotechnology
14.47 (0.24) (1.63%) as of 25 Sep
Market cap
$807.1M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

4D Molecular Therapeutics, Inc. (FDMT) Business Profile

Updated before January 2025

Company Overview

4D Molecular Therapeutics, Inc. (FDMT) is a clinical-stage biotechnology company specializing in the development of transformative gene therapies. Founded in 2013 and headquartered in Emeryville, California, FDMT was established with the mission of unlocking the full potential of gene therapy to treat a wide range of genetic diseases. The company was co-founded by Dr. David Kirn, a pioneer in gene therapy, and Dr. Melissa Kotterman, an expert in synthetic biology. Dr. David Kirn currently serves as the Chairman and CEO of the company, bringing decades of experience in the biotechnology and pharmaceutical industries.

FDMT leverages its proprietary Therapeutic Vector Evolution (TVE) platform to design and develop customized adeno-associated virus (AAV) vectors. These vectors are engineered to deliver genetic material to specific tissues and cells, addressing unmet medical needs in ophthalmology, cardiology, and pulmonology. The company’s innovative approach has positioned it as a leader in the gene therapy space, with a robust pipeline of clinical and preclinical programs.

Core Business Segments

Ophthalmology

FDMT’s ophthalmology segment focuses on developing gene therapies for inherited retinal diseases (IRDs) and other eye-related conditions. Key products in this category include:

  • 4D-150: A gene therapy candidate for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). This product is designed to inhibit VEGF, a protein that contributes to abnormal blood vessel growth in the retina.
  • 4D-125: A therapy targeting X-linked retinitis pigmentosa (XLRP), a rare genetic disorder that leads to progressive vision loss.

Cardiology

In the cardiology segment, FDMT is developing gene therapies to address genetic and acquired heart diseases. Notable products include:

  • 4D-310: A gene therapy candidate for Fabry disease, a rare genetic disorder caused by the buildup of a specific type of fat in the body’s cells.

Pulmonology

FDMT’s pulmonology segment focuses on developing therapies for severe respiratory diseases. Key products include:

  • 4D-710: A gene therapy candidate for cystic fibrosis (CF), designed to deliver functional copies of the CFTR gene to lung cells.

Business Model

FDMT operates on a vertically integrated business model that combines proprietary technology, in-house manufacturing capabilities, and a focus on high-value therapeutic areas. The company’s TVE platform allows it to design AAV vectors tailored to specific diseases and tissues, providing a competitive edge in the gene therapy market. FDMT generates revenue through strategic collaborations, licensing agreements, and milestone payments from its partners. Additionally, the company aims to commercialize its own therapies, which could provide a significant revenue stream in the future.

Strategic Direction

FDMT’s strategic direction is centered on advancing its clinical pipeline, expanding its TVE platform, and exploring new therapeutic areas. Key initiatives include:

  • Pipeline Expansion: The company plans to initiate additional clinical trials for its existing programs and explore new indications in ophthalmology, cardiology, and pulmonology.
  • Global Reach: FDMT aims to establish partnerships with international pharmaceutical companies to expand its market presence.
  • Sustainability Goals: The company is committed to sustainable manufacturing practices and minimizing its environmental footprint.
  • Innovation: FDMT continues to invest in research and development to enhance its TVE platform and discover novel AAV vectors.

Competitive Landscape

FDMT operates in a highly competitive market, with key competitors including:

  • Spark Therapeutics: A leader in gene therapy, known for its FDA-approved treatment for inherited retinal diseases.
  • Bluebird Bio: Specializes in gene therapies for severe genetic diseases and cancer.
  • REGENXBIO: Focuses on AAV-based gene therapies for retinal, metabolic, and neurodegenerative diseases.
  • Editas Medicine: Develops gene-editing therapies using CRISPR technology.

Despite the competition, FDMT’s proprietary TVE platform and focus on targeted gene delivery provide a significant competitive advantage.

Risk Factors

FDMT faces several risks that could impact its business operations and financial performance, including:

  • Regulatory Challenges: The gene therapy industry is subject to stringent regulatory requirements, which could delay product approvals.
  • Market Dependence: The company’s success is heavily reliant on the commercialization of its pipeline products.
  • Supply Chain Disruptions: Dependence on specialized raw materials and manufacturing processes makes the company vulnerable to supply chain issues.
  • Competition: Intense competition from established players and emerging startups could impact market share.
  • Financial Risks: As a clinical-stage company, FDMT relies on external funding and may face challenges in securing additional capital.

Recent Developments

FDMT has made significant progress in advancing its clinical programs and expanding its platform capabilities. Recent highlights include:

  • Clinical Trial Updates: Positive interim data from the Phase 1/2 clinical trials of 4D-150 and 4D-310, demonstrating safety and efficacy.
  • Partnerships: Collaboration with pharmaceutical companies to co-develop and commercialize gene therapies.
  • Manufacturing Expansion: Investment in state-of-the-art manufacturing facilities to support clinical and commercial production.
  • Global Developments: The COVID-19 pandemic highlighted the importance of gene therapy in addressing unmet medical needs, boosting interest in FDMT’s programs.

Investment Considerations

Strengths

  • Innovative Platform: The TVE platform provides a competitive edge in designing targeted gene therapies.
  • Robust Pipeline: A diverse portfolio of clinical and preclinical programs targeting high-value therapeutic areas.
  • Experienced Leadership: A seasoned management team with expertise in gene therapy and biotechnology.
  • Strategic Partnerships: Collaborations with leading pharmaceutical companies enhance development and commercialization efforts.

Risks

  • Clinical and Regulatory Risks: Uncertainty surrounding clinical trial outcomes and regulatory approvals.
  • Financial Dependence: Reliance on external funding and potential dilution of shareholder value.
  • Market Competition: Intense competition from established players and emerging startups.

Conclusion

4D Molecular Therapeutics, Inc. is at the forefront of the gene therapy revolution, leveraging its proprietary TVE platform to address unmet medical needs in ophthalmology, cardiology, and pulmonology. With a robust pipeline, strategic partnerships, and a commitment to innovation, FDMT is well-positioned for future growth. However, investors should carefully consider the risks associated with clinical-stage biotechnology companies. Overall, FDMT represents a compelling opportunity for those seeking exposure to the rapidly evolving gene therapy market.